Evolving technology trends and regulatory pathways in the tissue engineered product space

Published: 17 August 2021
Interview
William Fodor
William Fodor
Chief Scientific Officer, Biostage
William Fodor received his B.S. degree in Genetics and his Ph.D. degree in Molecular Genetics from The Ohio State University. He then completed his post-doctoral training in Immunobiology at the Yale School of Medicine (Mentor, R.A. Flavell). Dr. Fodor started his industrial career as a founding scientist of Alexion Pharmaceuticals, Inc. During his tenure at Alexion he directed the xenotransplantation, cell and tissue and organ engineering programs and advanced the program to include a pilot manufacturing facility for cell production. Dr. Fodor then moved to academia as an Associate Professor in the Center for Regenerative Biology at the University of Connecticut where he spent 3 years renovating his research to focus on stem cell biology for tissue repair. Dr. Fodor then returned to industry as Senior Director of Product Development at Viacell Inc., where he was responsible for various stem cell product development projects for hematologic indications as well as islet stem cell applications for diabetes. Following his tenure at Viacell, he continued his career in biotechnology as an independent consultant, serving many clients within the regenerative medicine field. Dr. Fodor’s relationship with Biostage was first as a consultant then as the Chief Scientific Officer, his current role.

William Fodor received his B.S. degree in Genetics and his Ph.D. degree in Molecular Genetics from The Ohio State University. He then completed his post-doctoral training in Immunobiology at the Yale School of Medicine (Mentor, R.A. Flavell). Dr. Fodor started his industrial career as a founding scientist of Alexion Pharmaceuticals, Inc. During his tenure at Alexion he directed the xenotransplantation, cell and tissue and organ engineering programs and advanced the program to include a pilot manufacturing facility for cell production. Dr. Fodor then moved to academia as an Associate Professor in the Center for Regenerative Biology at the University of Connecticut where he spent 3 years renovating his research to focus on stem cell biology for tissue repair. Dr. Fodor then returned to industry as Senior Director of Product Development at Viacell Inc., where he was responsible for various stem cell product development projects for hematologic indications as well as islet stem cell applications for diabetes. Following his tenure at Viacell, he continued his career in biotechnology as an independent consultant, serving many clients within the regenerative medicine field. Dr. Fodor’s relationship with Biostage was first as a consultant then as the Chief Scientific Officer, his current role.

Read now